文献速递产科母胎医学

妊娠晚期胎儿镜消融术治疗II型和III型血管前置

Third-trimester fetoscopic ablation therapy for types II and III vasa previa.
PubMed 文献 · Am J Obstet Gynecol · 2023-09-21

本研究回顾性分析2006至2022年间单中心20例II型或III型血管前置的单胎妊娠,在孕31周后行胎儿镜激光消融术。平均手术孕周32.0±0.6周,无围手术期并发症,所有患者血管均成功闭合(1例需二次手术),平均分娩孕周37.2±1.8周,70%经阴道分娩,新生儿结局良好。

要点

  • II型和III型血管前置在孕31至33周行胎儿镜激光消融术技术上可行,围手术期无并发症。
  • 20例患者均实现血管前置血管闭合,其中1例需第二次手术,术后均作为门诊患者管理。
  • 平均分娩孕周37.2±1.8周,70%经阴道分娩,3例新生儿入住NICU(1例呼吸窘迫综合征,2例高胆红素血症需光疗)。

核心结论

  • 在孕31至33周对II型和III型血管前置行激光消融术技术上可行,并获得了良好的结局。

研究设计与样本

  • 本研究为回顾性研究,纳入2006年至2022年间在单中心接受胎儿镜激光消融术的孕31周及以上的II型和III型血管前置单胎妊娠,最终分析20例。

主要发现

  • 84例转诊的血管前置患者中,57例未行激光消融:19例无血管前置或已消退,25例为I型血管前置(禁忌激光),13例为II型或III型但拒绝激光治疗。
  • 剩余27例接受激光消融的患者中排除7例(激光孕周<31周和/或双胎),最终纳入20例研究患者。
  • 胎儿镜激光消融的平均孕周为32.0±0.6周,总手术时间为62.1±19.6分钟,无围手术期并发症。
  • 所有患者均成功闭合血管前置血管(1例需第二次手术),随后均作为门诊患者管理。
  • 平均分娩孕周为37.2±1.8周,平均出生体重为2795±465克,70%经阴道分娩。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vasa previa is an obstetrical condition in which fetal vessels located near the cervix traverse the fetal membranes unprotected by underlying placenta. Type I vasa previa arises directly from a velamentous cord root, whereas types II and III arise from an accessory lobe or a distal lobe of the same placenta, respectively. Fetoscopic laser ablation for types II and III vasa previa is a novel therapeutic option with benefits that include surgical resolution of the vasa previa, avoidance of prolonged hospitalization, and opportunity for a term vaginal delivery. The potential risks of fetoscopy can be mitigated by delaying laser surgery until a gestational age of 31 to 33 weeks, immediately before anticipated hospitalized surveillance. OBJECTIVE: This study aimed to assess feasibility and outcomes of types II and III vasa previa patients treated via fetoscopic laser ablation in the third trimester. STUDY DESIGN: This is a retrospective study of singleton pregnancies with types II and III vasa previa treated with fetoscopic laser ablation at a gestational age ≥31 weeks at a single center between 2006 and 2022. Pregnancy and newborn outcomes were assessed. Continuous variables are expressed as mean±standard deviation. RESULTS: Of 84 patients referred for vasa previa, 57 did not undergo laser ablation: 19 either had no or resolved vasa previa, 25 had type I vasa previa (laser-contraindicated), and 13 had type II or III vasa previa but declined laser treatment. Of the remaining 27 patients who underwent laser ablation, 7 were excluded (laser performed at <31 weeks and/or twins), leaving 20 study patients. The mean gestational age at fetoscopic laser ablation was 32.0±0.6 weeks, and total operative time was 62.1±19.6 minutes. There were no perioperative complications. All patients had successful occlusion of the vasa previa vessels (1 required a second procedure). All patients were subsequently managed as outpatients. The mean gestational age at delivery was 37.2±1.8 weeks, the mean birthweight was 2795±465 g, and 70% delivered vaginally. Neonatal intensive care unit admission occurred in 3 cases: 1 for respiratory distress syndrome and 2 for hyperbilirubinemia requiring phototherapy. There were no cases of neonatal transfusion, intraventricular hemorrhage, sepsis, patent ductus arteriosus, or death. CONCLUSION: Laser ablation for types II and III vasa previa at 31 to 33 gestational weeks was technically achievable and resulted in favorable outcomes.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Chmait RH, Monson MA, Chon AH, et al. Third-trimester fetoscopic ablation therapy for types II and III vasa previa. Am J Obstet Gynecol. 2023. PMID: 37741533. doi:10.1016/j.ajog.2023.09.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。